SEC Tracker
Get the app

THC Therapeutics

THC Therapeutics Q1 FY23: revenue $0

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers THC Therapeutics reported for Q1 FY23, the quarter ended Oct 31, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0Against $0 in Q1 FY2210-Q income statement, on EDGAR
  2. Net income−$2.1MAgainst −$486K in Q1 FY2210-Q income statement, on EDGAR
  3. Cash and cash equivalents$4K−97% from $125K in Q1 FY2210-Q balance sheet, on EDGAR
  4. Cash from operations−$21KAgainst −$159K in Q1 FY2210-Q cash flow statement, on EDGAR

View on EDGAR

Open in the app

Get an email when THC Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3523 and related industry codes: the same peer list as the financial tables.

  1. Nature's Miracle Holding NMHI public float $519K, Jun 30, 2025
  2. Arts Way Manufacturing ARTW public float $4M, May 31, 2025
  3. Lindsay LNN public float $1.4B, Feb 28, 2026
  4. Alamo Group ALG public float $2.2B, Jun 30, 2025
  5. Agco AGCO public float $6.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.